Michael A. Metzger is the Chief Executive Officer at Syndax Pharmaceuticals Inc., a biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases. With an extensive background in the biopharmaceutical industry, Metzger has been instrumental in guiding Syndax through various stages of growth and development. Before joining Syndax, he held leadership positions at several notable companies, including Celgene Corporation, where he served as Senior Vice President and Head of Global Oncology. His experience in oncology and strategic leadership has been pivotal in advancing Syndax's mission to bring innovative treatments to patients. At Syndax, Metzger has been at the helm of the company's efforts to advance its pipeline of novel therapies. Under his leadership, Syndax has made significant progress in developing its lead product candidate, revumenib, which is being evaluated in clinical trials for the treatment of acute leukemias. Metzger's strategic vision and commitment to scientific excellence have helped position Syndax as a leader in the field of oncology. His role involves overseeing the company's overall operations, from research and development to commercialization, ensuring that Syndax continues to deliver on its promise to improve patient outcomes. Metzger's achievements extend beyond his role at Syndax. He is recognized in the industry for his contributions to advancing cancer research and treatment. His leadership has been marked by a dedication to fostering a collaborative and innovative environment at Syndax, which has attracted top talent and partnerships. Metzger holds a Bachelor of Science degree in Biology from Muhlenberg College and a Master of Science degree in Pharmacology from Thomas Jefferson University, further underscoring his deep understanding of the scientific and medical aspects of drug development.